These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30373751)

  • 1. Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients.
    Drennan S; Chiodin G; D'Avola A; Tracy I; Johnson PW; Trentin L; Steele AJ; Packham G; Stevenson FK; Forconi F
    Clin Cancer Res; 2019 Apr; 25(8):2503-2512. PubMed ID: 30373751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL.
    Chiodin G; Drennan S; Martino EA; Ondrisova L; Henderson I; Del Rio L; Tracy I; D'Avola A; Parker H; Bonfiglio S; Scarfò L; Sutton LA; Strefford JC; Forster J; Brake O; Potter KN; Sale B; Lanham S; Mraz M; Ghia P; Stevenson FK; Forconi F
    Blood Adv; 2022 Sep; 6(18):5494-5504. PubMed ID: 35640238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.
    Cheng S; Ma J; Guo A; Lu P; Leonard JP; Coleman M; Liu M; Buggy JJ; Furman RR; Wang YL
    Leukemia; 2014 Mar; 28(3):649-57. PubMed ID: 24270740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function.
    Coelho V; Krysov S; Steele A; Sanchez Hidalgo M; Johnson PW; Chana PS; Packham G; Stevenson FK; Forconi F
    Blood; 2013 Oct; 122(15):2664-72. PubMed ID: 23954894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.
    Blunt MD; Koehrer S; Dobson RC; Larrayoz M; Wilmore S; Hayman A; Parnell J; Smith LD; Davies A; Johnson PWM; Conley PB; Pandey A; Strefford JC; Stevenson FK; Packham G; Forconi F; Coffey GP; Burger JA; Steele AJ
    Clin Cancer Res; 2017 May; 23(9):2313-2324. PubMed ID: 27697994
    [No Abstract]   [Full Text] [Related]  

  • 7. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
    Liu TM; Woyach JA; Zhong Y; Lozanski A; Lozanski G; Dong S; Strattan E; Lehman A; Zhang X; Jones JA; Flynn J; Andritsos LA; Maddocks K; Jaglowski SM; Blum KA; Byrd JC; Dubovsky JA; Johnson AJ
    Blood; 2015 Jul; 126(1):61-8. PubMed ID: 25972157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation.
    Yeomans A; Thirdborough SM; Valle-Argos B; Linley A; Krysov S; Hidalgo MS; Leonard E; Ishfaq M; Wagner SD; Willis AE; Steele AJ; Stevenson FK; Forconi F; Coldwell MJ; Packham G
    Blood; 2016 Jan; 127(4):449-57. PubMed ID: 26491071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
    Till KJ; Pettitt AR; Slupsky JR
    J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-4 enhances expression and function of surface IgM in CLL cells.
    Aguilar-Hernandez MM; Blunt MD; Dobson R; Yeomans A; Thirdborough S; Larrayoz M; Smith LD; Linley A; Strefford JC; Davies A; Johnson PM; Savelyeva N; Cragg MS; Forconi F; Packham G; Stevenson FK; Steele AJ
    Blood; 2016 Jun; 127(24):3015-25. PubMed ID: 27002119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
    Guo A; Lu P; Galanina N; Nabhan C; Smith SM; Coleman M; Wang YL
    Oncotarget; 2016 Jan; 7(4):4598-610. PubMed ID: 26717038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status.
    Mockridge CI; Potter KN; Wheatley I; Neville LA; Packham G; Stevenson FK
    Blood; 2007 May; 109(10):4424-31. PubMed ID: 17255355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
    Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia.
    Manna A; Aulakh S; Jani P; Ahmed S; Akhtar S; Coignet M; Heckman M; Meghji Z; Bhatia K; Sharma A; Sher T; Alegria V; Malavasi F; Chini EN; Chanan-Khan A; Ailawadhi S; Paulus A
    Clin Cancer Res; 2019 Jul; 25(13):3974-3985. PubMed ID: 30940652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
    Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
    Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
    JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK.
    Krysov S; Steele AJ; Coelho V; Linley A; Sanchez Hidalgo M; Carter M; Potter KN; Kennedy B; Duncombe AS; Ashton-Key M; Forconi F; Stevenson FK; Packham G
    Blood; 2014 Nov; 124(20):3101-9. PubMed ID: 25170122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noncatalytic Bruton's tyrosine kinase activates PLCγ
    Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
    J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.
    Wodarz D; Garg N; Komarova NL; Benjamini O; Keating MJ; Wierda WG; Kantarjian H; James D; O'Brien S; Burger JA
    Blood; 2014 Jun; 123(26):4132-5. PubMed ID: 24829205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia.
    Del Papa B; Baldoni S; Dorillo E; De Falco F; Rompietti C; Cecchini D; Cantelmi MG; Sorcini D; Nogarotto M; Adamo FM; Mezzasoma F; Silva Barcelos EC; Albi E; Iacucci Ostini R; Di Tommaso A; Marra A; Montanaro G; Martelli MP; Falzetti F; Di Ianni M; Rosati E; Sportoletti P
    Clin Cancer Res; 2019 Dec; 25(24):7540-7553. PubMed ID: 31578228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.